Patent · US Active

Substituted amino-pyrimidine compound for use in a method for treatment and prevention of multiple sclerosis

US12251382B2 · kind B2 · utility

0Cited by

2References

32Claims

0Family size

Assignee

Merck Patent GmbH · DE

Inventors

Martin Dyroff · Wayland, US
David Mitchell · Edinburgh, GB
Orestis Papasouliotis · Geneva, CH

Key dates

Filing date	Jul 19, 2019
Grant date	Mar 18, 2025
Priority date	—
Expiry date	Dec 28, 2040

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P25/28
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Methods, compositions, and medical kits are useful for treating and preventing multiple sclerosis using 1-(4-(((6-amino-5-(4-phenoxyphenyl)pyrimidin-4-yl)amino)methyl)piperidin-1-yl)prop-2-en-1-one, or a pharmaceutically acceptable salt thereof, according to preferred dosing regimens.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.